pubmed-article:2237286 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2237286 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
pubmed-article:2237286 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
pubmed-article:2237286 | lifeskim:mentions | umls-concept:C0036974 | lld:lifeskim |
pubmed-article:2237286 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
pubmed-article:2237286 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:2237286 | pubmed:dateCreated | 1990-12-18 | lld:pubmed |
pubmed-article:2237286 | pubmed:abstractText | TNF plays a central role in septic shock induced by endotoxin or Gram-negative bacteria. Zymosan can elicit a septic shock-like syndrome in rodents in the absence of endotoxin. TNF and IL-6 release in mice treated with zymosan was investigated. One hour after intraperitoneal zymosan injection, maximal TNF levels were measured in serum, followed by IL-6 peak levels 1 h later. Treatment with a monoclonal antibody against TNF lowered zymosan-induced mortality from 63 to 11.6%, while maximal IL-6 levels were lowered by about 40%. Mechanisms triggering zymosan-induced cytokine release in murine macrophages were analysed in vitro. Cytokine release was only slightly triggered by uncoated zymosan particles. Thirty-nine per cent of TNF release by macrophages appeared to be triggered by zymosan-bound activated complement. Maximal TNF release also required the presence of natural antibodies against zymosan and zymosan-activated serum. In contrast, maximal IL-6 release was reached upon stimulation with zymosan-activated serum only, while the presence of zymosan particles lowered this response. We conclude that TNF is a crucial mediator in zymosan-induced shock. TNF release can be induced by different immunological pathways, without the need for the direct presence of endotoxins. Although IL-6 release during septic shock is partly dependent on TNF, in vitro trigger mechanisms for IL-6 and TNF differ remarkably. | lld:pubmed |
pubmed-article:2237286 | pubmed:language | eng | lld:pubmed |
pubmed-article:2237286 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2237286 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2237286 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2237286 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2237286 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2237286 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2237286 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2237286 | pubmed:month | Oct | lld:pubmed |
pubmed-article:2237286 | pubmed:issn | 0300-9475 | lld:pubmed |
pubmed-article:2237286 | pubmed:author | pubmed-author:BuurmanW AWA | lld:pubmed |
pubmed-article:2237286 | pubmed:author | pubmed-author:van der... | lld:pubmed |
pubmed-article:2237286 | pubmed:author | pubmed-author:von AsmuthE... | lld:pubmed |
pubmed-article:2237286 | pubmed:author | pubmed-author:MaessenJ GJG | lld:pubmed |
pubmed-article:2237286 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2237286 | pubmed:volume | 32 | lld:pubmed |
pubmed-article:2237286 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2237286 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2237286 | pubmed:pagination | 313-9 | lld:pubmed |
pubmed-article:2237286 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:meshHeading | pubmed-meshheading:2237286-... | lld:pubmed |
pubmed-article:2237286 | pubmed:year | 1990 | lld:pubmed |
pubmed-article:2237286 | pubmed:articleTitle | Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. | lld:pubmed |
pubmed-article:2237286 | pubmed:affiliation | Department of Surgery, University of Limburg, Maastricht, The Netherlands. | lld:pubmed |
pubmed-article:2237286 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2237286 | pubmed:publicationType | In Vitro | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2237286 | lld:pubmed |